Literature DB >> 32388560

Localized Hypertrophic Neuropathy as a Neoplastic Manifestation of KRAS-Mediated RASopathy.

M Adelita Vizcaino1, Allan Belzberg2,3, Shivani Ahlawat4, Sarra Belakhoua5,6,7, Liam Chen5, Verena Staedtke8,3, Fausto J Rodriguez5,9,3.   

Abstract

Localized hypertrophic neuropathy is a rare Schwann cell proliferation that usually affects single nerves from the extremities, and it is of unclear etiology in its pure form. RASopathies are a defined group of genetic diseases with overlapping clinical features, usually secondary to germline mutations in genes encoding either components or regulators of the RAS/MAPK pathway. Herein, we report an 11-year-old boy presenting with café au lait spots and right leg length discrepancy. A fascicular nerve biopsy of the tibial nerve demonstrated a Schwann cell proliferation with prominent onion-bulb formation, satisfying criteria for localized hypertrophic neuropathy. Molecular genetic analysis demonstrated identical KRAS mutations (c38_40dupGCG) in the peripheral nerve lesion and melanocytes from café au lait spots, but not in blood, supporting a diagnosis of a KRAS-mediated rasopathy with mosaicism. Immunohistochemical staining in the peripheral nerve lesion demonstrated strong pERK staining consistent with downstream MAPK pathway activation. This report suggests that at least a subset of localized hypertrophic neuropathies are bonafide, well-differentiated Schwann cell neoplasms developing through oncogenic RAS signaling, which provides new insights into the controversial entity historically known as localized hypertrophic neuropathy.
© 2020 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  KRAS; Localized hypertrophic neuropathy; Peripheral nerve; RASopathy; Schwann cell

Mesh:

Substances:

Year:  2020        PMID: 32388560      PMCID: PMC7241937          DOI: 10.1093/jnen/nlaa034

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  22 in total

1.  The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.

Authors:  A Pemov; H Li; R Patidar; N F Hansen; S Sindiri; S W Hartley; J S Wei; A Elkahloun; S C Chandrasekharappa; J F Boland; S Bass; J C Mullikin; J Khan; B C Widemann; M R Wallace; D R Stewart
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

2.  Intraneural perineurioma in neurofibromatosis type 2 with molecular analysis.

Authors:  Bartholomew White; Allan Belzberg; Shivani Ahlawat; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Clin Neuropathol       Date:  2020 Jul/Aug       Impact factor: 1.368

3.  BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper.

Authors:  Fausto J Rodriguez; Azra H Ligon; Iren Horkayne-Szakaly; Elisabeth J Rushing; Keith L Ligon; Natalie Vena; Denise I Garcia; J Douglas Cameron; Charles G Eberhart
Journal:  J Neuropathol Exp Neurol       Date:  2012-09       Impact factor: 3.685

4.  Soft tissue perineurioma in a patient with neurofibromatosis type 2: a tumor not previously associated with the NF2 syndrome.

Authors:  Clovis W Pitchford; Herbert S Schwartz; James B Atkinson; Justin M M Cates
Journal:  Am J Surg Pathol       Date:  2006-12       Impact factor: 6.394

5.  Hypertrophic neuropathy in Noonan syndrome with multiple lentigines.

Authors:  Claire Maridet; Guilhem Sole; Fanny Morice-Picard; Alain Taieb
Journal:  Am J Med Genet A       Date:  2016-03-07       Impact factor: 2.802

6.  Expansion of the RASopathies.

Authors:  William E Tidyman; Katherine A Rauen
Journal:  Curr Genet Med Rep       Date:  2016-07-01

7.  Paraspinal neurofibromas and hypertrophic neuropathy in Noonan syndrome with multiple lentigines.

Authors:  Erin Conboy; Radhika Dhamija; Margaret Wang; Jing Xie; P James Dyck; Alina G Bridges; Robert J Spinner; Amy C Clayton; Robert E Watson; Ludwine Messiaen; Dusica Babovic-Vuksanovic
Journal:  J Med Genet       Date:  2015-09-02       Impact factor: 6.318

8.  Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype.

Authors:  Hilde Brems; Magdalena Chmara; Mourad Sahbatou; Ellen Denayer; Koji Taniguchi; Reiko Kato; Riet Somers; Ludwine Messiaen; Sofie De Schepper; Jean-Pierre Fryns; Jan Cools; Peter Marynen; Gilles Thomas; Akihiko Yoshimura; Eric Legius
Journal:  Nat Genet       Date:  2007-08-19       Impact factor: 38.330

9.  PTPN11 mutation manifesting as LEOPARD syndrome associated with hypertrophic plexi and neuropathic pain.

Authors:  Marianna Spatola; Christian Wider; Thierry Kuntzer; Alexandre Croquelois
Journal:  BMC Neurol       Date:  2015-04-16       Impact factor: 2.474

10.  COSMIC: the Catalogue Of Somatic Mutations In Cancer.

Authors:  John G Tate; Sally Bamford; Harry C Jubb; Zbyslaw Sondka; David M Beare; Nidhi Bindal; Harry Boutselakis; Charlotte G Cole; Celestino Creatore; Elisabeth Dawson; Peter Fish; Bhavana Harsha; Charlie Hathaway; Steve C Jupe; Chai Yin Kok; Kate Noble; Laura Ponting; Christopher C Ramshaw; Claire E Rye; Helen E Speedy; Ray Stefancsik; Sam L Thompson; Shicai Wang; Sari Ward; Peter J Campbell; Simon A Forbes
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

View more
  2 in total

1.  Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.

Authors:  Christian Johnson; Deborah L Burkhart; Kevin M Haigis
Journal:  Cancer Discov       Date:  2022-04-01       Impact factor: 38.272

2.  A Patient with Noonan Syndrome with a KRAS Mutation Who Presented Severe Nerve Root Hypertrophy.

Authors:  Yoshihito Ando; Mikio Sawada; Tadataka Kawakami; Mitsuya Morita; Yoko Aoki
Journal:  Case Rep Neurol       Date:  2021-02-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.